Monday, 18 June 2018 - 4:31
  • it
  • de
  • en
  • fr

Newsletter

NASH sector heats up

Bloomberg yesterday reported that biotech Madrigal Pharmaceuticals  is weighing a sale after some early talks with large pharmaceutical groups. The news has made Madrigal’s shares jump by over 150% in the last month. Madrigal is a biotech based in Pennsylvania,…

Sanofi to sell Recipharm CMO business in UK for GBP54m

France-based Sanofi has sold to Sweden-based Recipharm AB its CMO business in UK, including the Manchester, UK-based Holmes Chapel manufacturing site, focusing on products for the respiratory drug market. The division yielded a revenue of  GBP51m over the last 12…

Here is the salary of pharma CEOs

The pharma sector is probably the one paying CEOs the highest salaries, especially in the US. A recent survey by MyLogIQ has stressed that the average salary of CEOs of S&P 500 firms is $12.1m, that is far below the…

Johnson & Johnson receives $2.1bn offer for Lifescan

Johnson & Johnson has announced today after trading had closed that it had received an acquisition offer by private equity Platinum Equity for Lifescan products. Lifescan is the leading brand in the blood sugar meters and Platinum Equity has valued…

Dry Eye, the Lifestyle Epidemic

What do all of the lifestyle choices below have in common? Viewing the 8,000 soldiers of the 3rdcentury Terracotta Army in Xi’an, China Farming rice in rural India Undergoing LASIK surgery Liking photos on your FaceBook account page Wearing contact…

Worrisome increase in spread of sexually-transmitted diseases

The spreading rate of sexually-transmitted diseases is worrisomely increasing in the UK. The most recent data demonstrate that syphilis cases have risen by 20% over the last year, while gonorrhea cases by 22%, and experts are particularly worried by a…

3,000 impending dismissals reported in Novo Nordisk

The Danish economic and financial daily Börsen has published a long article about Novo Nordisk and the rumors that started circulating yesterday, reporting that the company is planning cost cuts that would result in 3,000 dismissals and a downward revision…

Fortive offers $2.8bn for Johnson & Johnson’s ASP unit

US-based Johnson & Johnson has announced that the industrial Fortive Corp Group has submitted a $2.8bn bid–all in cash–to acquire  Advanced Sterilization Products (ASP) unit, which produces solutions to prevent infections in hospitals and other health units. ASP generated sales…

Recordati family reportedly weighing sale of controlling stake

The Recordati family is allegedly weighing a sale of its stake in the Recordati pharmaceutical group–51%–and its most probable buyers are private equities Cinven and Bain Capital.  The family made a first attempt at selling the company to a Chinese…

Pfizer: another biosimilar granted positive opinion by EMA CHMP

EMA Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion about Trazimera–biosimilar to Roche’s Herceptin (trastuzumab)– recommending a marketing authorization for patients with HER2 breast cancer. Trazimera is the fourth biosimilar by Pfizer to obtain positive…

NTC acquires part of Novartis’ ophthalmic portfolio

Italy-based pharmaceutical group NTC has acquired part of Novartis’ ophthalmic portfolio for the Spanish, Portuguese, Italian and Polish markets. The acquired products include  Colircusi Gentadexa (aminoglycoside), Colircusi Gentamicin and Oftalmolosa Cusi Gentamicina (aminoglycoside), Oftalmolosa Cusi Erythromycin (macrolide), Oftalmolosa Cusi Aureomycin…

1,000 R&D jobs in Bayer at risk

The economic and financial daily Wirtschaftswoche has published today a brief article reporting that Bayer has initiated an internal project called Super Bowl, to assess all of the company’s research centers. The management’s spokespersons have not disclosed any further details…

Olivier Brandicourt discloses new details about Sanofi’s new deal

Oliver Brandicourt, Sanofi CEO, has surprised analysts by announcing that his group is weighing new acquisitions. Indeed, Brandicourt has said in an interview to Bloomberg he is not aiming to acquire Pfizer’s Consumer Health division, instead he would prefer focusing…

Myriad Genetics acquires Counsyl for $375m

Myriad Genetics some hours ago announced that it has acquired for $375m Counsyl, a company that develops and markets non-invasive screening systems to determine whether fetuses risk to develop  genetic diseases. Myriad Genetics–headquartered in Salt Lake City-is a leader in…

Pfizer lies behind Mylan’s issues with Epipen

Mylan’s EpiPens is hard to be found in Canada and the UK and in severe shortage in the US. The problem is due to Pfizer, acting as a supplier to Mylan, which is experiencing issues in manufacturing enough product units…

Brain’s role in diabetes: new approach to insulin regulation

The prestigious journal Science has published today a significant study by a team of scientists led by Kasper Horst, from the Department of Endocrinology and Metabolism, Academic Medical Center of Amsterdam. The study reports data showing the brain’s role in…

Positive momentum for Amgen

Amgen has reported over the last few days a series of good news which has given a new boost to shares, rising by approximately 10% over the last three weeks. Firstly, Amgen’s migraine prevention treatment Aimovig (erenumab-aooe), co-developed with Novartis,…